Pilot Study Investigating the Use of the ReBuilder to Treat Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer
Withdrawn
- Conditions
- Peripheral Neuropathy
- Registration Number
- NCT02606110
- Lead Sponsor
- Eastern Regional Medical Center
- Brief Summary
The purpose of this study is to investigate the effect of the ReBuilder in the treatment of individuals with breast cancer and chemotherapy induced peripheral neuropathy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients with breast cancer referred to Physical Therapy for CIPN
- Physical Therapy Examination indicates use of Rebuilder for CIPN
- At least 18 years of age
- Signed informed consent for study population
- Willingness to complete study according to protocol
Exclusion Criteria
- Patients who do not have CIPN
- Patients <18 years of age
- Inability to or unwilling to sign informed consent
- Unable to read and understand the English language
- Preexisting sensory peripheral neuropathy from other comorbid conditions such as diabetes or alcoholism
- More than three (3) prior ReBuilder treatments; OR ReBuilder within the last 30 days, for sensory peripheral neuropathy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in touch and sensory by way of change in the Semmes-Weinstein Monofilament Testing one year Changes in touch and sensory by way of changes in Functional Gait Assessment One year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Eastern Regional Medical Center
🇺🇸Philadelphia, Pennsylvania, United States